I am a medical oncologist specializing in the treatment of genitourinary malignancies. My research interests are primarily in the area of clinical trials and I am an active participant in leading and accruing to trials in all areas of genitourinary oncology. My current major research focus is on bladder cancers and castrate resistant prostate cancer. I am the principal or co-investigator on approximately 15 clinical trials at the Cross Cancer Institute. I serve on the Canadian Uro-Oncology Group executive as well as the GU Executive of the CCTG. I co-chair the advanced bladder cancer disease oriented group for the CCTG.
TeachingMy major non-clinical academic focus is medical education and I have completed a Masters of Health Professions Education from the University of Illinois at Chicago. I participate in teaching and supervision of undergraduate students in the Faculty of Medicine and Dentistry as well as post graduate residents in the medical oncology training program. I have also organized and provided educational seminars in the form of continuing medical education for practicing physicians. I have been fortunate enough to have been awarded the Rutherford award for Excellence in Undergraduate Teaching in 2006 and in 2011 I received the 3M National Teaching Fellowship Award.
Our research program is highly collaborative within the Department of Oncology as well as across faculties in developing translational research programs. Investigators in genitourinary oncology (including myself) have been actively pursuing collaborations with colleagues in the Faculty of Pharmacology and the Department of Surgery. Currently I have >80 peer reviewed publications as well as numerous abstracts and conference presentations due to the success of our research environment.
In the GU group we are working closely with our pre phase I program as well as the phase I clinical trials group to bring new drugs to human clinical trials. Our site is also active in collection of real world data that brings direct impact to changes in management for patients in Canada living with GU cancers. We participate in the Canadian Kidney Cancer Information System, The Canadian Bladder Cancer Information System as well as the development of a national research consortium for outcomes research in advanced prostate cancer.
Our research team consists of 3 Medical Oncologists with interests and expertise in GU Cancer, four clinical trials nurses and 3 data coordinators. We have an extensive research program in clinical trials for all patients with GU cancers.